Oruka Therapeutics (ORKA) Net Equity Issued and Repurchased (2010 - 2026)

Oruka Therapeutics' Net Equity Issued and Repurchased history runs 14 years deep, the most recent figure standing at $1.7 million for Q1 2026.

• In Q1 2026, Net Equity Issued and Repurchased changed N/A year-over-year to $1.7 million; the TTM figure through Mar 2026 stood at -$617000.0 (changed N/A YoY), while the FY2025 annual figure was $671000.0, up 1142.59% from the prior year.
• Net Equity Issued and Repurchased for Q1 2026 stood at $1.7 million, up from $562000.0 in the prior quarter.
• The five-year high for Net Equity Issued and Repurchased was $3.0 million in Q1 2024, with the low at -$2.9 million in Q4 2024.
• The 3-year median for Net Equity Issued and Repurchased is $562000.0 (2025), against an average of $462800.0.
• Peak annual rise in Net Equity Issued and Repurchased reached 119.53% in 2025, while the deepest fall reached 119.53% in 2025.
• Oruka Therapeutics' Net Equity Issued and Repurchased stood at -$2.9 million in 2024, then surged by 119.53% to $562000.0 in 2025, then jumped by 202.14% to $1.7 million in 2026.
• Business Quant data shows ORKA's Net Equity Issued and Repurchased at $1.7 million in Q1 2026, $562000.0 in Q4 2025, and -$2.9 million in Q4 2024.